Apyx (APYX) Upgraded to Buy: Here's What You Should Know
- Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/03/2024
|
Renuvion Named #1 Trusted Body Contouring Technology by Doctors*
- Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla.
- 08/13/2024
|
Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this time all participants have been placed in a listen-only more.
- 08/11/2024
|
Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates
- Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago.
- 08/08/2024
|
Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health
- Renuvion is the only device FDA-cleared for contracting subcutaneous tissue CLEARWATER, Fla. , June 26, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical technology.
- 06/26/2024
|
Apyx Medical Corporation (APYX) Q1 2024 Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matt Hill - Chief Financial Officer Conference Call Participants Phillip Paul Dantoin - Piper Sandler Frank Takkinen - Lake Street Capitals Matt Hewitt - Craig-Hallum Capital George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the First Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. [Operator Instructions].
- 05/11/2024
|
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
- Apyx Medical (APYX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.10 per share a year ago.
- 05/09/2024
|
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th. Management will host a conference call at 8:00 a.m. Eastern Time on May 9th to discuss the results of the quarter, and to host a question and answer sessi.
- 04/25/2024
|
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users' Summit
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Apyx Medical”; “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users' Summit is taking place in Las Vegas from April 12-13, 2024. The Renuvion Users' Summit brings together a diverse group of dedicated professionals in cosmetic and plastic surgery from 13 countries to share new research, applications, and c.
- 04/11/2024
|
Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript
- Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript
- 03/21/2024
|
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
- Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.17 per share a year ago.
- 03/21/2024
|
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary: Total revenue of $14.7 million, an increase of 16% year-over-year.
- 03/21/2024
|
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st. Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a questio.
- 03/04/2024
|
Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that its Renuvion technology will be featured in three educational sessions at the upcoming American Academy of Cosmetic Surgery's 40th Annual Scientific Meeting, to be held in New Orleans, LA from February 22 – 24. “Apyx Medical is pleased to see Renuvion featured.
- 02/21/2024
|
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. “We are excited to see the publication of this.
- 01/22/2024
|
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter 2023 Revenue Summary: Total revenue in a range of approximately $14.2 to $14.6 million, representing growth of 13% to 16% year-over-year. Advanced Energy revenue in a.
- 01/08/2024
|
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. “Matt joins our executive leadership team with over 30 years of fin.
- 11/28/2023
|
Apyx Medical Corporation (APYX) Q3 2023 Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Charles Goodwin - President & CEO Tara Semb - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum George Sellers - Stephens Dave Turkaly - JMP Securities Operator Please stand by. Hello, and welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Apyx Medical Corporation.
- 11/09/2023
|
Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the Company and its subsidiaries have entered into a new, five-year credit agreement with Perceptive Credit Holdings IV, LP (“Perceptive”), an affiliate of Perceptive Advisors. The Perceptive Credit Agreement provides for a facility of up to $45 million in senior secured term.
- 11/09/2023
|
Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023. Third Quarter 2023 Financial Summary: Total revenue of $12.0 million, up 31% year-over-year. Advanced Energy revenue of $9.8 million,.
- 11/09/2023
|
Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the following upcoming investor conferences: The Stephens Annual Investment Conference at the Nashville Grand Hyatt in Nashville, TN Management will participate in a fireside chat on Tuesday, November 14 at 12:00 p.m. Eastern Time. The Craig-Hall.
- 11/07/2023
|
Are Medical Stocks Lagging Apyx Medical (APYX) This Year?
- Here is how Apyx Medical (APYX) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
- 10/26/2023
|
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2023 will be released before the market opens on Thursday, November 9th. Management will host a conference call at 8:00 a.m. Eastern Time on November 9th to discuss the results of the quarter, and to host a question and a.
- 10/02/2023
|
Apyx Medical Corporation (APYX) Q2 2023 Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Charles Goodwin - President & CEO Tara Semb - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group George Sellers - Stephens Frank Takkinen - Lake Street Capital Markets Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal 2023 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode.
- 08/12/2023
|
Apyx Medical (APYX) Reports Q2 Loss, Misses Revenue Estimates
- Apyx Medical (APYX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.16 per share a year ago.
- 08/10/2023
|
Is Apyx Medical (APYX) Stock Outpacing Its Medical Peers This Year?
- Here is how Apyx Medical (APYX) and Haemonetics (HAE) have performed compared to their sector so far this year.
- 05/16/2023
|
Apyx Medical Corporation (APYX) Q1 2023 Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Charlie Goodwin - President & CEO Tara Semb - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Operator Hello and welcome, ladies and gentlemen, to the First Quarter of Fiscal Year 2023 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode.
- 05/11/2023
|
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2022 Financial Results on March 16, 2023
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2022 will be released before the market opens on Thursday, March 16th. Management will host a conference call at 8:00 a.m.
- 02/16/2023
|
Archon Capital Ups Stake in Apyx Medical (APYX) After Q3 Results
- Fintel reports that Archon Capital Management LLC has filed a 13G/A form with the SEC disclosing ownership of 3,452,030 shares of Apyx Medical Corp (APYX).
- 11/23/2022
|
Apyx Medical Corporation (APYX) Q3 2022 Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Charles Goodwin - President and Chief Executive Officer Tara Semb - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Matthew O'Brien - Piper Sandler Kyle Bauser - Lake Street Capital Markets Dave Turkaly - JMP Securities Russell Cleveland - RENN Capital Operator Hello and welcome, ladies and gentlemen to Third Quarter of 2022 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in listen-only mode.
- 11/13/2022
|
Apyx Medical (APYX) Reports Q3 Loss, Misses Revenue Estimates
- Apyx (APYX) delivered earnings and revenue surprises of -41.67% and 24.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q2 2022 Results - Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Charles Goodwin – President and Chief Executive Officer Tara Semb – Chief Financial Officer Conference Call Participants Dave Turkaly – JMP Securities Matt Hewitt – Craig-Hallum Capital Group Kyle Bauser – Lake Street Capital Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of 2022 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode.
- 08/14/2022
|
Apyx Medical's Renuvion Scores FDA Approval To Eliminate Sagging Neck
- The FDA has granted 510(k) clearance for Apyx Medical Corporation's (NASDAQ: APYX) Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance of lax skin in the neck and submental region. Renuvion is a proprietary helium plasma and.
- 07/18/2022
|
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® and J-Plasma® in surgical markets, today announced that financial results for the second quarter of fiscal year 2022 will be released after the market closes on Thursday, August 11th. Management will host a conference call at 5:00 p.m. Eastern Time on August 11th to discuss the results of
- 06/30/2022
|
Why Are Apyx Medical Shares Trading Higher Today?
- Apyx Medical Corporation (NASDAQ: APYX) has FDA received 510(k) clearance for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures to treat moderate to severe wrinkles and.
- 05/26/2022
|
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q1 2022 Results - Earnings Call Transcript
- Apyx Medical Corporation (NASDAQ:APYX ) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Charles Goodwin - President & Chief Executive Officer Tara Semb - Chief Financial Officer, Treasurer & Secretary Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Operator Hello, and welcome, ladies and gentlemen to the First Quarter of 2022 Earnings Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode.
- 05/12/2022
|
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
- Apyx (APYX) delivered earnings and revenue surprises of -30.77% and 7.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2022 Financial Results on May 12, 2022
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the first quarter of fiscal year 2022 will be released before the market opens on Thursday, May 12th. Management will host a conference call at 8:00 a.m. Eastern Time on
- 04/04/2022
|
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2021 Results - Earnings Call Transcript
- Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2021 Results - Earnings Call Transcript
- 03/17/2022
|
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2021 will be released before the market opens on Thursday, March 17th. Management will host a conference call at 8:00 a.m. Eastern Tim
- 01/27/2022
|
Apyx Medical Corp (APYX) CEO Charles Goodwin on Q3 2021 Results - Earnings Call Transcript
- Apyx Medical Corp (APYX) CEO Charles Goodwin on Q3 2021 Results - Earnings Call Transcript
- 11/11/2021
|
Earnings Preview: Apyx Medical (APYX) Q3 Earnings Expected to Decline
- Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/04/2021
|
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2021 Financial Results on November 11, 2021
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the third quarter of fiscal year 2021 will be released after the market closes on Thursday, November 11th. Management will host a conference call at 5:00 p.m. Eastern Ti
- 10/04/2021
|
Apyx (APYX) Moves 10.9% Higher: Will This Strength Last?
- Apyx (APYX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 09/28/2021
|
Apyx Medical Corporation Announces Appointment of Wendy Levine to the Company's Board of Directors
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021. Ms. Levine will serve as a Director and member of the Regulatory Compliance Committee. “I am pleas
- 08/30/2021
|
Apyx Medical Shares Increases Over 19% Intraday: Why It Happened
- The shares of Apyx Medical Corp (NASDAQ: APYX) increased by over 19% during intraday trading. This is why it happened.
- 08/12/2021
|
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q2 2021 Results - Earnings Call Transcript
- Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates
- Apyx (APYX) delivered earnings and revenue surprises of 14.29% and 25.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Apyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2021 and updated its financial outlook for the full year ending December 31, 2021. Second Quarter 2021 Financial Summary: Total revenue of $1
- 08/12/2021
|
Will Apyx Medical (APYX) Report Negative Earnings Next Week? What You Should Know
- Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/05/2021
|
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the second quarter of fiscal year 2021 will be released before the market opens on Thursday, August 12th. Management will host a conference call at 8:00 a.m. Eastern Tim
- 07/12/2021
|
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
- Apyx (APYX) delivered earnings and revenue surprises of 0.00% and 9.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2021
|
Apyx Medical Corporation's (APYX) CEO Charlie Goodwin on Q1 2021 Results - Earnings Call Transcript
- Apyx Medical Corporation's (APYX) CEO Charlie Goodwin on Q1 2021 Results - Earnings Call Transcript
- 05/12/2021
|
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
- Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/05/2021
|
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q4 2020 Results - Earnings Call Transcript
- Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q4 2020 Results - Earnings Call Transcript
- 03/31/2021
|
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
- Apyx (APYX) delivered earnings and revenue surprises of 69.23% and 3.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/31/2021
|
Apyx Medical: Q4 Earnings Insights
- Shares of Apyx Medical (NASDAQ:APYX) decreased 2.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 75.00% year over year to ($0.04), which beat the estimate of ($0.11).
- 03/31/2021
|
Apyx Medical's Earnings: A Preview
- Apyx Medical (NASDAQ:APYX) announces its next round of earnings this Wednesday, March 31. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.
- 03/30/2021
|
Will Apyx Medical (APYX) Report Negative Earnings Next Week? What You Should Know
- Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/24/2021
|
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 31, 2021
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2020 will be released before the market opens on Wednesday, March 31. Management will host a conference call at 8:00 a.m. Eastern Time
- 02/01/2021
|
Apyx Medical's (APYX) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Apyx Medical (APYX).
- 02/01/2021
|
Here's Why Momentum Investors Will Love Apyx Medical (APYX)
- Does Apyx Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/29/2021
|
Apyx (APYX) Upgraded to Buy: Here's Why
- Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/18/2021
|
Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2020 Revenue Results
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2020. Preliminary Fourth Quarter 2020 Revenue Summary: Total Q4 revenue in a range of approximately $10.9 to $11.
- 01/13/2021
|
Apyx Medical Corporation to Participate in the ICR Conference 2021
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the ICR Conference 2021, which is being held virtually from January 11th-14th. Management will participate in a fireside chat on Thursday, January 14th at 9:15
- 01/05/2021
|
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
- Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/15/2020
|
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2020 Results - Earnings Call Transcript
- Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November and December
- CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences: The Stifel 2020 Virtual Healthcare Conference Management will present on Monday, November 16 at 4:40 p.m. Eastern T
- 11/03/2020
|
JCPenney Files Draft Asset Purchase Agreement
- JCPenney today announced that it has filed a draft asset purchase agreement to sell the Company.
- 10/20/2020
|
NLCS Game 7 Photos: Dodgers advance to World Series
- Take a look at the photos of the Dodgers playing the Atlanta Braves in Game 7 of the NL Championship Series on Sunday, Oct. 18 in Arlington, Texas.
- 10/19/2020
|
Alexander: Dodgers emphasized doing ‘something special’
- They’re a third of the way there as they try to wipe out a 3-1 series deficit, beating Atlanta in Game 5.
- 10/17/2020
|
Dodgers extend NLCS with home runs from Will Smith, Corey Seager
- Seager hit two home runs in the game, but it was Smith’s three-run home run in the sixth inning that gave the Dodgers a lead. Walker Buehler will start Game 6 on Saturday.
- 10/17/2020
|
Mookie Betts makes the small plays as Dodgers stave off elimination
- The All-Star’s third-inning catch and sixth-inning single paved the way for two critical plays in Game 5 of the NLCS.
- 10/17/2020
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against STAAR Surgical Company (STAA)
- The Law Offices of Frank R. Cruz reminds investors of the upcoming October 19, 2020 deadline to file a lead plaintiff motion in the class action filed
- 10/16/2020
|
COVID-19 Impacts and Actionable Research: Coffee Bean Market Analysis, Trends, and Forecasts, 2019-2024 by SpendEdge
- Coffee Bean market size is expected to grow over USD 7 billion at a Compound Annual Growth Rate (CAGR) of 7.00% during the forecast period of 2019-20
- 10/15/2020
|
Hexavest Inc. Decreases Holdings in Arthur J. Gallagher & Co. (NYSE:AJG)
- Hexavest Inc. decreased its holdings in Arthur J. Gallagher & Co. (NYSE:AJG) by 7.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 87,839 shares of the financial services provider’s stock after selling 7,444 shares during the period. Hexavest Inc.’s holdings in Arthur J. Gallagher & […]
- 10/14/2020
|
COVID-19 Impacts and Actionable Research: Coffee Bean Market Analysis, Trends, and Forecasts, 2019-2024 by SpendEdge
- Coffee Bean market size is expected to grow over USD 7 billion at a Compound Annual Growth Rate (CAGR) of 7.00% during the forecast period of 2019-24
- 10/09/2020
|
Nuveen Asset Management LLC Has $9.33 Million Stake in J & J Snack Foods Corp. (NASDAQ:JJSF)
- Nuveen Asset Management LLC decreased its stake in shares of J & J Snack Foods Corp. (NASDAQ:JJSF) by 4.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 73,387 shares of the company’s stock after selling 3,046 shares during the quarter. Nuveen […]
- 10/03/2020
|
Notice of Lead Plaintiff Deadline for Shareholders in the STAAR Surgical Company Class Action Lawsuit
- Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Central District of California on behalf of purchaser
- 10/02/2020
|
Handelsbanken Fonder AB Purchases New Stake in J & J Snack Foods Corp (NASDAQ:JJSF)
- Handelsbanken Fonder AB purchased a new stake in J & J Snack Foods Corp (NASDAQ:JJSF) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,179 shares of the company’s stock, valued at approximately $404,000. Several other institutional investors have also bought and sold […]
- 09/29/2020
|
California State Teachers Retirement System Sells 408 Shares of J & J Snack Foods Corp (NASDAQ:JJSF)
- California State Teachers Retirement System cut its stake in shares of J & J Snack Foods Corp (NASDAQ:JJSF) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,576 shares of the company’s stock after selling 408 shares during the period. […]
- 09/27/2020
|
J & J Snack Foods (NASDAQ:JJSF) Rating Lowered to Sell at BidaskClub
- BidaskClub cut shares of J & J Snack Foods (NASDAQ:JJSF) from a hold rating to a sell rating in a research report sent to investors on Wednesday, BidAskClub reports. Other research analysts have also recently issued reports about the company. Zacks Investment Research cut J & J Snack Foods from a hold rating to a […]
- 09/24/2020
|
Bank of Montreal Can Has $251,000 Stock Position in J & J Snack Foods Corp (NASDAQ:JJSF)
- Bank of Montreal Can increased its stake in J & J Snack Foods Corp (NASDAQ:JJSF) by 147.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,085 shares of the company’s stock after purchasing an additional 1,241 shares during the period. Bank […]
- 09/24/2020
|
National Convenience Distributors Raises Over $1.2 Million For Charity
- With roots dating back more than 120 years, National Convenience Distributors is the parent entity of three main operating divisions doing business as
- 09/23/2020
|
J & J Snack Foods Corp (NASDAQ:JJSF) Shares Bought by Engineers Gate Manager LP
- Engineers Gate Manager LP increased its stake in shares of J & J Snack Foods Corp (NASDAQ:JJSF) by 25.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,015 shares of the company’s stock after purchasing an additional 1,019 shares during the […]
- 09/22/2020
|
Q3 2020 EPS Estimates for Arthur J Gallagher & Co (NYSE:AJG) Lowered by Piper Sandler
- Arthur J Gallagher & Co (NYSE:AJG) – Stock analysts at Piper Sandler cut their Q3 2020 earnings per share estimates for Arthur J Gallagher & Co in a research report issued to clients and investors on Thursday, September 17th. Piper Sandler analyst P. Newsome now anticipates that the financial services provider will post earnings per […]
- 09/20/2020
|
A Closer Look At WisdomTree MidCap Dividend ETF (NYSEARCA:DON)
- With total assets of ~$2.52 billion, the WisdomTree MidCap Dividend ETF has a nicely diversified portfolio of 334 stocks.
- 09/18/2020
|
STAA SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Staar Surgical Company
- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities
- 09/15/2020
|
Timber Logistics Market- Roadmap for Recovery from COVID-19 | Increasing Demand For Paper-based Packaging to boost the Market Growth | Technavio
- The Global Timber Logistics Market will grow by $ 3.50 bn during 2020-2024
- 09/12/2020
|
Global Dental Imaging Market by Product, Application, End User and Region - Forecast to 2026 - ResearchAndMarkets.com
|
STAA SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies STAAR Surgical Company of Class Action and Encourages Shareholders to Contact the Firm
- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against STAAR Surgical Company (
- 08/25/2020
|
Notice of Lead Plaintiff Deadline for Shareholders in the STAAR Surgical Company Class Action Lawsuit
- Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Central District of California on behalf of purchaser
- 08/24/2020
|
Notable Insider Buys Last Week: Avis Budget, Xerox And Many More
- Insider buying can be an encouraging signal for potential investors during periods of uncertainty.
A number of executives and other insiders returned to the buy window last week...
- 08/22/2020
|
State Street Corp Sells 18,192 Shares of Apyx Medical Corp (NASDAQ:APYX)
- State Street Corp reduced its stake in shares of Apyx Medical Corp (NASDAQ:APYX) by 3.0% during the 1st quarter, HoldingsChannel reports. The fund owned 597,454 shares of the company’s stock after selling 18,192 shares during the period. State Street Corp’s holdings in Apyx Medical were worth $2,145,000 at the end of the most recent quarter. […]
- 08/11/2020
|
Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates
- Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
Recap: Apyx Medical Q2 Earnings
- Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q2 results.Quarterly Results Earnings per share were down 7.69% year over year to ($0.14), which beat the estimate of ($0.21).Revenue of $4,296,000 declined by 34.59% from the same period last year, which beat the estimate of $1,960,000.Guidance Apyx Medical hasn't issued any earnings guidance for the time being.Apyx Medical hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on APYXTime: 08:00 AMET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/39030/indexl.htmlPrice Action 52-week high: $8.59Company's 52-week low was at $2.81Price action over last quarter: Up 55.28%Company Profile Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.See more from Benzinga * P/E Ratio Insights for Apyx Medical * 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/10/2020
|
Apyx Medical Corporation Reports Second Quarter 2020 Financial Results
- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2020.
- 08/10/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
- Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2020
|
Apyx Medical (APYX) to Release Quarterly Earnings on Monday
- Apyx Medical (NASDAQ:APYX) is set to issue its quarterly earnings data before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link. Apyx Medical (NASDAQ:APYX) last posted its quarterly […]
- 08/03/2020
|
WeissLaw LLP: Apyx Medical Corporation is the Subject of a Legal Investigation
- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, California and Georgia, announces an investigation of Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical Corp.," or the "Company").
- 07/31/2020
|
Edwin Rios wins one for Dodgers with two-run home run in 13th inning
- Rios’ home run and a strong effort by the bullpen give the Dodgers a two-game mini-sweep of the Astros.
- 07/30/2020
|
STRATA Skin Sciences (NASDAQ:SSKN) and Apyx Medical (NASDAQ:APYX) Financial Contrast
- STRATA Skin Sciences (NASDAQ:SSKN) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation. Risk and Volatility STRATA Skin Sciences has a beta of 2.1, suggesting that its […]
- 07/16/2020
|
Electrosurgical Devices Market: Growth, Trends & Forecast 2020-2025 - ResearchAndMarkets.com
|
Lifshitz Law Firm, P.C. Announces Investigation of Acer Therapeutics, Inc. (ACER), Advanced Disposal Services, Inc. (ADSW), Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunomedics, Inc. (IMMU), National General Holdings Corp. (NGHC) and Zuora, Inc. (ZUO)
- Acer Therapeutics, Inc. (ACER)
- 07/09/2020
|
Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of the companies listed below.
- 07/03/2020
|
NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher
- NanoString Technologies (NSTG) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
- 07/02/2020
|
Global Electrosurgery Devices Market By Product, By Application, By End-user, By Region, Forecast & Opportunities, 2025
- This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Electrosurgery Devices Market By Product (Electrosurgical Generators (Radiofrequency, Ultrasonic, Argon Plasma, Cryoablation, Microwave, Combination and Smoke Evacuators), Electrosurgical Instruments (Electrosurgical Electrodes (Monopolar, Bipolar), Pencils (Monopolar, Bipolar), Forceps, Cryoprobes, Nano knifes and Others)), Accessories), By Application (Orthopedics, Oncology, Cardiovascular, General, Cosmetic, Neurology and Others), By End-user (Hospitals, Ambulatory Surgical Centers and Others), By Region, Forecast & Opportunities, 2025
- 06/30/2020
|
Here is What Hedge Funds Think About Apyx Medical Corporation (APYX)
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 06/25/2020
|
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020
- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the second quarter of fiscal year 2020 will be released before the market opens on Monday, August 10.
- 06/25/2020
|
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020
- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, markete
- 06/25/2020
|
P/E Ratio Insights for Apyx Medical
- Looking into the current session, Apyx Medical Inc. (NASDAQ: APYX) shares are trading at $5.60, after a 17.22% spike. Moreover, over the past month, the stock increased by 19.72%, but in the past year, fell by 2.39%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.The stock is currently above from its 52 week low by 99.75%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Medical Devices stocks, and capitalize on the lower share price observed over the year.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P; 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Apyx Medical Inc. has a lower P/E than the aggregate P/E of 6.44 of the Medical Devices industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session * Apyx Medical: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/23/2020
|
Apyx Spikes 45% In Pre-Market On Nod To Sell Helium Products In New Countries
- Shares in Apyx Medical Corp. (APYX) spiked 45% in pre-market trading after the medical devices manufacturer won regulatory approval to sell its Helium Plasma technology products in five new countries.The stock leaped to $6.93. Apyx received approval to sell its Helium Plasma technology products in Australia, Brazil, Israel, Taiwan and Thailand. The company said it has contracted with distributors to market its products in each country. The products are sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market.Renuvion, which is used for cosmetic medical procedures such as dermal resurfacing, is a device using the helium technology to apply energy beneath the skin, causing a contraction effect that’s gentle on tissue. J-Plasma is a device used in cosmetic surgery for cutting, coagulation, and ablation of tissue.“We have been focused on pursuing regulatory clearances in international markets as one of our key strategic priorities to enhance Apyx Medical’s long-term growth profile,” said Apyx CEO and President Charlie Goodwin. “This strategy is based on the prudent expansion of our commercial footprint outside the U.S. by securing the requisite product registrations for our Helium Plasma Technology products, and identifying strong distribution partners in each respective market.”Goodwin added that he sees great growth opportunity in Brazil, which is estimated to be the second largest cosmetic surgery market in the world in terms of both the total number of procedures performed and the number of surgeons.“We shipped an initial commercial order to our distributor in Brazil in late-June and we expect to ship our initial commercial orders to each of the other new countries over the second half of 2020,” Goodwin said.Shares in Apyx have been hit hard this year, plunging some 43%. The stock rose 2.1% to $4.78 as of Monday’s close.Five-star analyst Matthew O'Brien at Piper Sandler maintained a Buy rating on the stock with a $7 price target, saying that the regulatory approval is an "important step" for building out the company's international customer base and should generate a "nice chunk" of growth in the coming years.O'Brien added that although Apyx’s shares are still down significantly year-to-date, he believes the company remains in sound financial shape and he expects the stock to recover as the coronavirus pandemic begins to subside.Related News: Merck’s Gardasil Receives FDA Nod For Expanded Cancer Indications Evoke Pharma Pops 86% On FDA Approval Of Gimoti Nasal Spray Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug More recent articles from Smarter Analyst: * Sarepta, Codiak BioSciences Team Up For Neuromuscular Disease Targeting * Sanofi, Translate Bio Ramp Up Billion-Dollar mRNA Vaccine Collaboration * Spirit Aero Falls After-Hours On Financial Breach Warning * PG&E; Launches $5.23B Public Offering To Fund Ch.11 Emergence
- 06/23/2020
|
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
- 06/23/2020
|
Apyx Medical Corporation Announces Regulatory Clearance to Market and Sell its Helium Plasma Technology Products in Five New Countries
- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that the Company has obtained regulatory approval to market and sell its Helium Plasma Technology products in five new countries: Australia, Brazil, Israel, Taiwan and Thailand. The Company has contracted with distributors to market and sell its products in each country.
- 06/22/2020
|
Apyx Medical Corporation Announces Regulatory Clearance to Market and Sell its Helium Plasma Technology Products in Five New Countries
- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, markete
- 06/22/2020
|
NOTICE For Investors In NASDAQ: APYX Shares: Update in Lawsuit against Apyx Medical Corporation announced by Shareholders Foundation
- San Diego, California--(Newsfile Corp. - June 16, 2020) - The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Apyx Medical Corporation (NASDAQ: APYX) shares.Investors, who purchased shares of Apyx Medical Corporation (NASDAQ: APYX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.On April 17, 2019, a lawsuit was filed against Apyx Medical Corporation /k/a/ Bovie Medical Corporation over alleged Securities ...
- 06/16/2020
|
Kaskela Law LLC Announces Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm
- Kaskela Law LLC announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company's stockholders.
- 06/06/2020
|
Lifshitz Law Firm, P.C. Announces Investigation of Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunomedics, Inc. (IMMU), and Zuora, Inc. (ZUO)
- NEW YORK, June 05, 2020 -- Apyx Medical Corporation (APYX) Lifshitz Law Firm, P.C. announces investigation into possible breaches of fiduciary duty by certain of Apyx’s.
- 06/05/2020
|
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Apyx Medical Corporation - APYX
- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) resulting from allegations that Apyx may have issued materially misleading business information to the investing public.
- 05/29/2020
|
Lifshitz Law Firm, P.C. Announces Investigation of Advance Auto Parts, Inc., (AAP), Apyx Medical Corporation (APYX), Dycom Industries, Inc. (DY), Qumu Corporation (QUMU), Provident Financial Services, Inc. (PFS), SB One Bancorp (SBBX), and Zuora, Inc. (ZUO)
- Advance Auto Parts, Inc. (AAP)
- 05/28/2020
|
Why Apyx (APYX) Stock Might be a Great Pick
- Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/26/2020
|
Liver Surgery and Neurosurgery Electrosurgical Units (ESUs) Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis with Regional Analysis 2020 to 2026
- May 26, 2020 (Profound via COMTEX) --
Liver Surgery and Neurosurgery Electrosurgical Units (ESUs) Market 2020 Report offers a professional and in-depth study...
- 05/26/2020
|
Bipolar Electrosurgical Devices Market Research Analysis, Size, Share, Growth, Outlook, Opportunities, Trends, Leading Players and Forecast 2026
- May 25, 2020 (CDN Newswire via Comtex) --
This Global Bipolar Electrosurgical Devices Market business report is the result of incessant efforts lead by...
- 05/25/2020
|
Kaskela Law LLC Announces Stockholder Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm
- Kaskela Law LLC is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company’s stockholders.
- 05/23/2020
|
Kaskela Law LLC Announces Stockholder Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm
- Kaskela Law LLC is investigating Apyx Medical Corporation (NASDAQ: APYX) (“Apyx” or the “Company”) on behalf of the Company’s stockholders. In Septemb
- 05/23/2020
|
Will Apyx Medical Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor of Apyx Medical
- 05/19/2020
|
SHAREHOLDER ALERT: Apyx Medical Corporation Officers and Directors Under Investigation by Schubert Law Firm for Allegedly Misleading Statements Concerning Its December 2018 FDA Application for Expanded Uses of J-Plasma Technology
- Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of stockholders of Apyx Medical Corporation (NASDAQ: APYX) related to the company's statements regarding its December 2018 application to the U.S. Food and Drug Administration for expanded uses of Apyx's J-Plasma technology—the company's key growth product.
- 05/18/2020
|
Lifshitz Law Firm, P.C. Announces Investigation of Advance Auto Parts, Inc., (AAP), Apyx Medical Corporation (APYX), Dycom Industries, Inc. (DY) and Wright Medical Group N.V. (NASDAQ: WMGI)
- NEW YORK, May 15, 2020 -- Advance Auto Parts, Inc. (AAP) Lifshitz Law Firm announces investigation into possible breaches of fiduciary duty by certain of Advance Auto Parts’.
- 05/15/2020
|
Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q1 2020 Results - Earnings Call Transcript
- Apyx Medical Corp (NASDAQ:APYX) Q1 2020 Results Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Charlie Goodwin - President and Chief Exec
- 05/13/2020
|
Apyx Medical Corp (APYX) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Apyx Medical Corp (NASDAQ: APYX)Q1 2020 Earnings CallMay 11, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen, and welcome to the first quarter fiscal-year 2020 earnings call for Apyx Medical Corporation [Operator instructions].
- 05/12/2020
|
Apyx Medical (APYX) Reports Q1 Loss, Misses Revenue Estimates
- Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Apyx Medical: Q1 Earnings Insights
- Shares of Apyx Medical (NASDAQ:APYX) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share fell 42.86% over the past year to ($0.20), which beat the estimate of ($0.25).Revenue of $4,997,000 less by 14.19% year over year, which missed the estimate of $5,200,000.Outlook Apyx Medical hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 11, 2020View more earnings on APYXTime: 08:01 PM ETWebcast URL: https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/36949/indexl.htmlRecent Stock Performance Company's 52-week high was at $8.5952-week low: $2.81Price action over last quarter: down 24.31%Company Profile Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.See more from Benzinga * Recap: Contura Energy Q1 Earnings * Recap: Vuzix Q1 Earnings * Recap: WAVE Life Sciences Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/11/2020
|
Apyx Medical Corporation Reports First Quarter 2020 Financial Results
- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its first quarter ended March 31, 2020.
- 05/11/2020
|
Apyx Medical Corporation Reports First Quarter 2020 Financial Results
- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, markete
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 7)
• Acceleron Pharma Inc (...
- 05/08/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
Update in Lawsuit against Apyx Medical Corporation (NASDAQ: APYX) announced by Shareholders Foundation
- On April 17, 2019, a lawsuit was filed against Apyx Medical Corporation /k/a/ Bovie Medical Corporation over alleged Securities Laws Violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint, that, as a result, the clinical study did not support the Company’s application for regulatory clearance, that, as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. On September 3, 2019, an amended complaint was filed, and on October 3, 2019, the defendants filed their motion to dismiss the case.
- 05/04/2020
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apyx Medical Corporation and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ:APYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx admitted on March 16, 2020, that its financial results for multiple periods, including the 12 months ending December 31, 2019, the quarterly statements for the three and nine-months periods ending September 30, 2018, and the three months ending March 31, 2019, could no longer be considered reliable and would require restating.
- 04/20/2020
|
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Apyx Medical Corporation (APYX) and Encourages Investors to Contact the Firm
- PHILADELPHIA, PA / ACCESSWIRE / April 20, 2020 / Kaskela Law LLC is investigating Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ:APYX) on behalf of the Company's investors. ...
- 04/20/2020
|
APYX Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
- Johnson Fistel, LLP is investigating potential claims on behalf of Apyx Medical Corporation (formerly Bovie Medical) ("Apyx" or the "Company") (APYX) against certain of its officers and directors. In 2019, a Securities Class Action Complaint was filed on behalf of those who purchased securities of Apyx between August 1, 2018 through April 1, 2019. According to the lawsuit, defendants throughout the Class Period made false and misleading statements and failed to disclose that: (1) the clinical study on the use of J-Plasma, a plasma-based surgical product for cutting, coagulation, and ablation of soft tissue, for dermal resurfacing had not met its primary efficacy endpoint; (2) the clinical study did not support Apyx's application for regulatory clearance; (3) Apyx was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants' positive statements about Apyx's business, operations, and prospects were materially false and misleading and lacked a reasonable basis.
- 04/18/2020
|
APYX MEDICAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Apyx Medical Corporation - APYX
- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Apyx Medical Corporation (NasdaqGS: APYX).
- 04/18/2020
|
Apyx Medical Corp (NASDAQ:APYX) Short Interest Update
- Apyx Medical Corp (NASDAQ:APYX) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 527,200 shares, a decrease of 44.9% from the March 15th total of 957,200 shares. Based on an average trading volume of 93,600 shares, the days-to-cover ratio is […]
- 04/16/2020
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apyx Medical Corporation and Encourages Investors with Losses to Contact the Firm
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ:APYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx admitted on March 16, 2020, that its financial results for multiple periods, including the 12 months ending December 31, 2019, the quarterly statements for the three and nine-months periods ending September 30, 2018, and the three months ending March 31, 2019, could no longer be considered reliable and would require restating.
- 04/15/2020
|
Goldman Sachs Group Inc. Boosts Stock Position in Apyx Medical Corp (NASDAQ:APYX)
- Goldman Sachs Group Inc. lifted its position in shares of Apyx Medical Corp (NASDAQ:APYX) by 1,148.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 212,439 shares of the company’s stock after purchasing an additional 195,417 shares during the period. Goldman […]
- 04/15/2020
|
Apyx Medical Corp (NASDAQ:APYX) Shares Sold by AQR Capital Management LLC
- AQR Capital Management LLC cut its position in Apyx Medical Corp (NASDAQ:APYX) by 29.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,777 shares of the company’s stock after selling 6,472 shares during the period. AQR Capital Management LLC’s holdings in Apyx Medical were worth […]
- 04/14/2020
|
APYX LOSS NOTICE: ROSEN, A TOP FIRM, Continues to Investigate Securities Claims Against Apyx Medical Corporation – APYX
- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) resulting from allegations that Apyx may have issued materially misleading business information to the investing public.
- 04/12/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apyx Medical Corporation - APYX
- Pomerantz LLP is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
- 04/12/2020
|
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2020 Financial Results on May 11, 2020
- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the first quarter of fiscal year 2020 will be released before the market opens on Monday, May 11.
- 04/07/2020
|
ValuEngine Downgrades Apyx Medical (NASDAQ:APYX) to Buy
- Apyx Medical (NASDAQ:APYX) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports. APYX has been the subject of a number of other reports. Piper Sandler decreased their price target on shares of Apyx Medical from to in a research note on […]
- 04/04/2020
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apyx Medical Corporation and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 31, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ:APYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx admitted on March 16, 2020, that its financial results for multiple periods, including the 12 months ending December 31, 2019, the quarterly statements for the three and nine-months periods ending September 30, 2018, and the three months ending March 31, 2019, could no longer be considered reliable and would require restating.
- 03/31/2020
|
Apyx Medical Corp (NASDAQ:APYX) Sees Significant Decline in Short Interest
- Apyx Medical Corp (NASDAQ:APYX) was the recipient of a large drop in short interest in March. As of March 13th, there was short interest totalling 957,200 shares, a drop of 5.2% from the February 27th total of 1,010,000 shares. Based on an average daily trading volume, of 86,600 shares, the days-to-cover ratio is currently 11.1 […]
- 03/30/2020
|
Reviewing Titan Medical (NASDAQ:TMDI) and Apyx Medical (NASDAQ:APYX)
- Apyx Medical (NASDAQ:APYX) and Titan Medical (NASDAQ:TMDI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership. Valuation and Earnings This table compares Apyx Medical and Titan Medical’s gross revenue, earnings per […]
- 03/28/2020
|
Apyx Medical (NASDAQ:APYX) Stock Price Up 6.8%
- Shares of Apyx Medical Corp (NASDAQ:APYX) rose 6.8% during mid-day trading on Tuesday . The company traded as high as $3.58 and last traded at $3.46, approximately 198,110 shares were traded during mid-day trading. An increase of 111% from the average daily volume of 93,700 shares. The stock had previously closed at $3.24. APYX has […]
- 03/26/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) (follow-on rally from Friday's news of FDA authorization
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Charles Schwab Investment Management Inc. Grows Stake in Apyx Medical Corp (NASDAQ:APYX)
- Charles Schwab Investment Management Inc. grew its position in Apyx Medical Corp (NASDAQ:APYX) by 4.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,185 shares of the company’s stock after purchasing an additional 3,281 shares during the quarter. Charles Schwab Investment Management […]
- 03/22/2020
|
Apyx Medical (NASDAQ:APYX) Price Target Cut to
- Apyx Medical (NASDAQ:APYX) had its target price lowered by Piper Sandler from to in a report published on Tuesday morning, The Fly reports. Piper Sandler also issued estimates for Apyx Medical’s Q1 2020 earnings at ($0.22) EPS, Q2 2020 earnings at ($0.21) EPS, Q3 2020 earnings at ($0.21) EPS, Q4 2020 earnings at ($0.21) EPS, […]
- 03/21/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
Piper Sandler Weighs in on Apyx Medical Corp's Q1 2020 Earnings (NASDAQ:APYX)
- Apyx Medical Corp (NASDAQ:APYX) – Stock analysts at Piper Sandler issued their Q1 2020 earnings estimates for shares of Apyx Medical in a research note issued on Monday, March 16th. Piper Sandler analyst M. O’brien anticipates that the company will earn ($0.22) per share for the quarter. Piper Sandler also issued estimates for Apyx Medical’s […]
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
Apyx Medical Corp (NASDAQ:APYX) Given Average Recommendation of "Buy" by Brokerages
- Apyx Medical Corp (NASDAQ:APYX) has been given an average recommendation of “Buy” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month […]
- 03/17/2020
|
Apyx Medical Corp (NASDAQ:APYX) Stake Boosted by State Street Corp
- State Street Corp increased its stake in Apyx Medical Corp (NASDAQ:APYX) by 10.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 615,646 shares of the company’s stock after purchasing an additional 57,969 shares during the quarter. State Street Corp owned approximately 1.80% […]
- 03/17/2020
|
Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook
- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary unaudited financial
- 03/16/2020
|
Apyx Medical Corp (NASDAQ:APYX) is Archon Capital Management LLC's 3rd Largest Position
- Archon Capital Management LLC lessened its stake in Apyx Medical Corp (NASDAQ:APYX) by 1.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,690,026 shares of the company’s stock after selling 50,000 shares during the quarter. Apyx Medical accounts for […]
- 03/15/2020
|
Blockpass partners with J. Rotbart & Co. to offer precious metal services for PASS Club members » CryptoNinjas
- Blockchain KYC-as-a-Service platform Blockpass and J. Rotbart & Co., today unveiled a partnership to offer precious metal services to PASS Club
- 03/10/2020
|
Apyx Medical (APYX) to Release Earnings on Monday
- Apyx Medical (NASDAQ:APYX) is set to release its earnings data after the market closes on Monday, March 16th. Analysts expect Apyx Medical to post earnings of ($0.16) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. Shares of APYX stock opened at $6.30 […]
- 03/09/2020
|
-$0.16 EPS Expected for Apyx Medical Corp (NASDAQ:APYX) This Quarter
- Equities research analysts expect Apyx Medical Corp (NASDAQ:APYX) to post ($0.16) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Apyx Medical’s earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.13). Apyx Medical reported earnings per share […]
- 03/05/2020
|
Apyx Medical (NASDAQ:APYX) Upgraded to Strong-Buy at ValuEngine
- Apyx Medical (NASDAQ:APYX) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday, ValuEngine reports. A number of other research analysts have also recently commented on APYX. BidaskClub raised shares of Apyx Medical from a “sell” rating to a “hold” rating in […]
- 03/03/2020
|
California Public Employees Retirement System Increases Stock Position in Apyx Medical Corp (NASDAQ:APYX)
- California Public Employees Retirement System increased its position in Apyx Medical Corp (NASDAQ:APYX) by 133.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,793 shares of the company’s stock after purchasing an additional 37,616 shares during the quarter. California Public Employees Retirement System’s holdings […]
- 03/02/2020
|
